BlueLinx Q2 Sales Rise 4.4% to $814M, Adjusted EBITDA Jumps 33% to $35.6M
BXC sits 54% above its 52-week low of $44.78.
Summary
BlueLinx reported Q2 2026 net sales of $814 million, up 4.4% year-over-year, with adjusted EBITDA of $35.6 million, a 33% increase. The company provided Q3 margin guidance and highlighted strong free cash flow and a healthy balance sheet.
Key Events · Earnings and Guidance · BXC
-
Q2 Sales Beat Consensus
Net sales of $814 million exceeded the $793.72 million consensus, up 4.4% year-over-year, driven by the Disdero acquisition and higher volumes in key categories.
-
Adjusted EBITDA Up 33%
Adjusted EBITDA reached $35.6 million, a 33% increase from $26.8 million in Q2 2025, with margin expanding 100 basis points to 4.4% of net sales.
-
Strong Free Cash Flow
Free cash flow improved by $45 million year-over-year to $8.8 million, supported by $11.2 million in operating cash flow and lower capital expenditures.
-
Healthy Balance Sheet
Ended Q2 with $318 million in cash, total liquidity of $655 million, and a net leverage ratio of 0.6x, with no material debt maturities until 2029.
Analysis · BXC · Trade & Services
A strong second quarter saw BlueLinx top consensus sales estimates while profitability improved sharply. Adjusted EBITDA climbed 33% to $35.6 million, fueled by margin expansion across both specialty and structural products. Free cash flow came in at $8.8 million, and the quarter ended with $318 million in cash and a net leverage ratio of just 0.6x. Management's Q3 margin guidance points to continued solid performance. The results underscore the company's ability to grow profitably in a challenging housing market, supported by its acquisition strategy and operational discipline.
At the time of this filing, BXC was trading at $69.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $501.7M. The 52-week trading range was $44.78 to $87.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.